ALK-Abelló A/S
ALK-B
Rankning i aktier
#2327
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Aktiekurs
$36.45
Marknadsvärde
$8.09B
Förändring (1 dag)
-3.46%
Förändring (1 år)
10.38%
Land
DK
Handel ALK-Abelló A/S (ALK-B)
Kategori
Healthcare
Antal utestående aktier för ALK-Abelló A/S (ALK-B)
Antal utestående aktier per June 2026: 221.88M
Enligt de senaste finansiella rapporterna och aktiekursen för ALK-Abelló A/S är det aktuella antalet utestående aktier 221.88M. I slutet av December 2023 hade företaget 221.15M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för ALK-Abelló A/S (ALK-B) från 2004 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 221.88M | 0.25% |
| 2024 | 221.32M | 0.08% |
| 2023 | 221.15M | 0.29% |
| 2022 | 220.50M | 0.51% |
| 2021 | 219.39M | 0.49% |
| 2020 | 218.32M | 0.14% |
| 2019 | 218.01M | 0.31% |
| 2018 | 217.33M | 9.53% |
| 2017 | 198.43M | 1.07% |
| 2016 | 196.33M | 1.15% |
| 2015 | 194.09M | 0.46% |
| 2014 | 193.20M | 0.00% |
| 2013 | 193.20M | -0.87% |
| 2012 | 194.91M | -1.53% |
| 2011 | 197.94M | -0.14% |
| 2010 | 198.22M | -0.49% |
| 2009 | 199.19M | -0.34% |
| 2008 | 199.88M | -0.33% |
| 2007 | 200.53M | -0.74% |
| 2006 | 202.02M | 0.47% |
| 2005 | 201.07M | -0.60% |
| 2004 | 202.28M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 14.43% |
US
|
|
| 396.00M | 78.48% |
US
|
|
| 478.91M | 115.84% |
AU
|
|
| 62.19M | -71.97% |
NL
|
|
| - | - |
CH
|
